 AUSTIN, Texas, May 3, 2021 PRNewswire -- Aeglea BioTherapeutics, Inc. NASDAQ: AGLE, a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced that it has completed patient randomization for PEACE Pegzilarginase Effect on Arginase 1 Deficiency Clinical Endpoints, the pivotal Phase 3 clinical trial investigating pegzilarginase for the treatment of Arginase 1 Deficiency ARG1-D. ARG1-D is a rare, progressive disease characterized by high levels of arginine which results in severe mobility limitations due to spasticity, seizures, developmental delay, intellectual disability and early mortality. 